Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Manufacturing Snag May Stall Portola's Bevyxxa Launch

Executive Summary

Company has priced its Factor Xa anticoagulant at $15 per capsule, on par with competitors, and is gearing up for a launch, but it first must resolve manufacturing issues with FDA as it scales up to commercial capacity.


Related Content

CHMP Readies ‘Outstanding Issues’ Lists For Products Nearing EU Review End
Finance Watch: Former GSK CEO Witty, R&D Head Slaoui Join VC Firms
Portola's AndexXa Antidote For Xarelto And Eliquis Finally On The Way
Portola's Bevyxxa Poised To Capture Niche Novel Anticoagulant Market
Portola Seeks Narrower Label For AndexXa Antidote After FDA Rebuff


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts